Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology based therapies for patients in need.

Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.

Vision & Values

At Zenas, we strive to be a truly innovative company. Our vision is to be a global leader in bringing innovative immunology based medicines to patients around the world. We are guided by our core value system: TRUE Innovation.

Transparency

We will communicate openly and honestly, even when having difficult conversations.

Relationships

We are unified in the high value we place on both our internal relationships with each other and our external relationships with our partners and collaborators.

Urgency

We are all fully engaged with a sense of urgency to realize our vision.

Excellence

We aspire to the highest levels of teamwork and results-oriented execution, and we will measure and communicate our results.

Innovation

We will be creative, open to change, adaptable to new ways of thinking and operating with a “why not?” attitude.

Leadership

Lonnie Moulder
Founder & Executive Chair

Lonnie Moulder headshot

Mr. Moulder, Founder of Zenas BioPharma, serves as our Executive Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a fully-integrated Boston based oncology-focused biopharmaceutical company) and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.

Hua Mu, Ph.D., MD
Chief Executive Officer

Hua Mu headshot

Dr. Hua Mu serves as Chief Executive Officer at Zenas. Prior to joining Zenas, Dr. Mu was the co-founder of Overland Pharmaceuticals and served as Interim CEO and CMO, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as CSO and President of R&D and later CMO of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was SVP and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was EVP and CMO at Hutchison MediPharma in China. He previously held Medical Director and Head of Medical Affairs positions at several global pharmaceutical companies in the US, including Roche, Abraxis BioScience (Celgene/BMS), Biogen, and Genentech. With extensive experience in building and leading R&D organizations and international collaborations, Dr. Mu has a proven track record of successful development and approval of new drugs in China and around the globe. He participated in and led the development of more than 20 innovative drug candidates in multiple therapeutic areas, including three drugs approved in the US and global market, four in China, and an NDA currently under priority review in China.

Dr. Mu conducted translational and clinical research at the University of California, San Francisco and at the University of Washington Medical School before joining industry in 1999. He received his PhD in Genetic Epidemiology from the University of California at Berkeley and completed his post-doctorate training at University of California at San Francisco School of Medicine and University of Washington Medical School. Dr. Mu received his MD degree from West China University of Medical Sciences.

Joe Farmer
President & Chief Operating Officer

Joe Farmer headshot

Mr. Farmer is the President and Chief Operating Officer of Zenas BioPharma. He is an accomplished biopharma executive with approximately 25 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, he served as Chief Operating Officer at Xilio Therapeutics, a pre-clinical oncology company, where he led the general and administrative, business development, and business operations functions. Prior to Xilio he was the General Counsel and Corporate Secretary at TESARO, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team through its acquisition by GlaxoSmithKline in 2019. He previously served as Chief Corporate Counsel at Cubist Pharmaceuticals through its acquisition by Merck in 2015 and as General Counsel at two publicly traded companies, including AMAG Pharmaceuticals, where he was also the Chief Administrative Officer. He began his career as a corporate attorney at Testa Hurwitz & Thibeault.

Throughout his career, Mr. Farmer has been involved in numerous large and complex financing, business development, and M&A transactions, together approaching $20 billion in aggregate value. He received his J.D. from Boston College Law School and his B.A. in economics from Boston University.

Simon Lowry, MD
Chief Medical Officer

Simon Lowry, MD, Chief Medical Officer, Zenas Bio

Dr. Lowry is the Chief Medical Officer at Zenas BioPharma. Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK. He received his BA from Trinity Hall, Cambridge University, and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

Caroline Chevalier
Senior Vice President, Human Resources

Caroline headshot

Ms. Chevalier is the Senior Vice President, Human Resources at Zenas BioPharma. Ms. Chevalier leads the Human Resource Operations function for the U.S. and has more than 15 years of human resources experience within the pharmaceutical and biotechnology industry. Prior to joining Zenas, she served as Vice President, Human Resources at Deciphera Pharmaceuticals. Prior to Deciphera, Ms. Chevalier was Senior Director, Total Rewards & Human Resource Operations at TESARO where she was responsible for developing and implementing scalable policies and programs to attract and retain talent in a high growth, global organization. Ms. Chevalier also held several roles of increasing responsibility at Cubist Pharmaceuticals in her 12 year tenure during which she gained experience across all aspects of Human Resources, supporting the organization through commercialization, global expansion and multiple acquisitions. Ms. Chevalier received a B.A. in Economics from Boston College.

Eric Haltom
Senior Vice President, Global Clinical Development Operations

Eric Haltom headshot

Mr. Haltom is the Senior Vice President, Global Clinical Development Operations of Zenas BioPharma. He is an accomplished biopharma executive with 30 years of clinical research and operational experience working with emerging biotechnology companies at all stages of clinical development.  Prior to joining Zenas, he served as Senior Vice President, Clinical Operations at Deciphera Pharmaceuticals, a commercial oncology company, where he established and led the Clinical Operations and Clinical Business Operations function for 5 years. Prior to Deciphera he was the Head of Clinical Operations at Shire, where he led the global clinical operations group and was a key member of the Clinical Development leadership team.

Throughout his career, Mr. Haltom has been involved in various start up and established global organizations building comprehensive clinical operations teams. He received his B.A in business from Saint Anselm College.

Richard Mountfield, Ph. D.
Senior Vice President, Global Head of Regulatory Affairs and Quality

Richard Mountfield headshot

Dr. Richard Mountfield is the Senior Vice President, Global Head of Regulatory Affairs at Zenas BioPharma and has spent over 25 years in the biopharmaceutical industry, with experience in all stages of drug development. Dr. Mountfield joins Zenas from Constellation Pharmaceuticals where he was Senior Vice President, Regulatory Affairs and Quality, a member of the Leadership Team, and a key member of the team that sold the company to MorphoSys AG for approximately $1.7 billion in 2021. Prior to Constellation, he served as Senior Vice President of Regulatory Affairs and Drug Development at Boston Pharmaceuticals, where he was responsible for helping build the organization, including establishing and recruiting multiple line functions and contributing to the in-licensing of numerous assets with multiple indications. Prior to that, he held positions of increasing responsibility in Regulatory Affairs and Drug Development at Celyad, Novartis, and Boehringer Ingelheim. He has also been involved in the registration and approval of multiple products in both the US and EU. Earlier in his career he was involved in late discovery and early clinical development at Roche and Novo Nordisk. Dr. Mountfield holds a Ph.D. in biochemistry from the University of Wales, Aberystwyth, UK.

Gan Wei, Ph.D.
Senior Vice President, Global Technical Operations

Gan Wei headshot

Dr. Wei is Senior Vice President, Global Technical Operations at Zenas BioPharma. Prior to joining Zenas, he served as Vice President, Interim Head of Technical Operations at Voyager Therapeutics. Previously, Dr. Wei was the Senior Director of Biologics Process Development at Momenta Pharmaceuticals, followed by Executive Director of Biologics Drug Substance and Analytical Sciences at TESARO. Dr. Wei has over 20 years of experience in the biopharmaceutical industry spanning biologics process development and cGMP manufacturing support, including commercialization to life cycle management.

Dr. Wei received a Ph.D. and M.S. in Chemical and Biochemical Engineering from the University of Maryland, Baltimore County, and an M.S. and B.S. in Biochemical Engineering from East China University of Science and Technology.

Keith Wilcoxen, Ph.D.
Senior Vice President, Global Research

Keith Wilcoxen headshot

Dr. Wilcoxen serves as Senior Vice President, Global Research at Zenas BioPharma. Prior to joining Zenas, he was the Vice President of Diligence and Non-Clinical Development, followed by Vice President of Translational Research at Boston Pharmaceuticals where he was a core member of the Research & Development Leadership team. Dr. Wilcoxen has more than 20 years of experience in the biopharmaceutical industry including the successful submission of multiple investigational new drug applications. He previously held roles of increasing responsibility in non-clinical drug development and discovery with TESARO, Eisai, Neurocrine Biosciences, and Pfizer.

Dr. Wilcoxen received a Ph.D. in Chemistry from Scripps Research Institute and a B.A. in Chemistry from Northwestern University.

Board of Directors

Lonnie Moulder, Founder & Executive Chair

Mr. Moulder, Founder of Zenas BioPharma, serves as our Executive Chair and is the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund. Prior to establishing Tellus BioVentures, he cofounded TESARO (a fully-integrated Boston based oncology-focused biopharmaceutical company) and served as CEO and Director until its acquisition by GlaxoSmithKline in January 2019. Mr. Moulder previously served as President and CEO of Abraxis BioScience. Prior to Abraxis he served as Vice Chairman of Eisai Corporation of North America following Eisai’s acquisition of MGI PHARMA, where he served as President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.

Mr. Moulder is a Temple University Trustee and Chair of the Trustee Committee for Research. He is a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder serves on the Board of Directors for Zai Lab, Helsinn Group and Trevena and for the Tellus BioVentures portfolio companies: Aegle Therapeutics, Dianthus Therapeutics, Interius BioTherapeutics and TamuroBio. He received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.

James Boylan, Chief Executive Officer, Enavate Sciences

James Boylan leads Enavate Sciences and is an accomplished health care executive, entrepreneur and innovator with nearly three decades of experience. Mr. Boylan most recently served as President and Head of Investment Banking of SVB Leerink, where he architected and led the transformation of Leerink Swann into an industry-leading health care investment bank that was acquired by SVB Financial in 2019. Across his 12 years at SVB Leerink and prior 12 years as a Managing Director at Merrill Lynch, Mr. Boylan has worked with hundreds of life sciences and biotechnology companies to develop strategy and complete transactions in capital markets and mergers & acquisitions.

Mr. Boylan earned an MBA in finance from the Columbia Business School and a BS in finance from Lehigh University.

Patrick Enright, Managing Director, Longitude Capital

Patrick Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche), and Sandoz. Mr. Enright currently serves on the boards of Aptinyx, CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals, Orbus Therapeutics, Rivus Pharmaceuticals, Vera Therapeutics, as well as the National Venture Capital Association.

Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.

Tomas Kiselak, Managing Member, Fairmount Funds

Mr. Kiselak serves as Managing Member at Fairmount Funds Management LLC, a healthcare investment fund he co-founded in April 2016. Prior to Fairmount Funds, Mr. Kiselak served as a managing director at RA Capital Management LLC, based in Boston. In addition to his responsibilities at Fairmount Funds, Mr. Kiselak serves as a Director at Viridian Therapeutics, Inc., and a strategic advisor to Dianthus Therapeutics, Inc. He received his BA in Neuroscience and Economics from Amherst College.

Hongbo Lu, Ph.D, Partner, Vivo Capital

Hongbo Lu, Ph.D., is a Partner of Vivo Capital. Dr. Lu has close to 20 years of healthcare investment experience in both public securities and private companies. Prior to joining Vivo, she served as a Managing Partner at Lilly Asia Ventures (LAV). Prior to that, she served as a Managing Director at OrbiMed Advisors. She previously served on the boards of Turning Point Therapeutics, CrownBio, Avedro Inc., and Passage Bio and was extensively involved in the company incubations of ADARx Pharmaceuticals, Alpiscience, Geneception Therapeutics, Perfuse Therapeutics, Terns Pharmaceuticals, and Ronovo Pharmaceuticals since inception.

Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an MBA. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University.

Marietta Wu, MD, Ph.D., MBA, Managing Director, Quan Capital

Dr. Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China and the US. She is a founding member of Zai Lab (NASDAQ: ZLAB) and served as Chief Operating Officer and Director of the company prior to Quan Capital. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry.  Dr. Wu is also a frequent speaker and an author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business. Dr. Wu serves on the board of Citrine, Crescendo Biologics, Innoforce, Kira Pharmaceutical, MEDx Translational Medicine and Zidan Medical.

John Orloff, MD, Venture Partner, Agent Capital

Dr. Orloff is Venture Partner at Agent Capital, a healthcare venture capital firm based in Waltham, MA. Prior to Agent Capital, he served as EVP and Global Head of R&D for Alexion, where his leadership in expanding the development pipeline from three to 30 programs supported the recent $39 billion acquisition of Alexion by AstraZeneca. Prior to Alexion, Dr. Orloff was Global Head of R&D and Chief Scientific Officer at Baxalta, and has also held executive leadership roles with Novelion, Baxter International, Merck Serono, Novartis and Merck Research Laboratories.

Before entering the biopharmaceutical industry, he was a faculty member at the Yale University School of Medicine. Dr. Orloff received an undergraduate degree in chemistry from Dartmouth College, earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.

Hua Mu, Ph.D., MD, Chief Executive Officer

Dr. Hua Mu serves as Chief Executive Officer at Zenas. Prior to joining Zenas, Dr. Mu was the co-founder of Overland Pharmaceuticals and served as Interim CEO and CMO, while also serving as Venture Partner at Hillhouse Capital. Prior to Overland, Dr. Mu served as CSO and President of R&D and later CMO of Simcere Pharmaceutical Group and President of Simcere of America Inc. Before Simcere, he was SVP and Global Head of Product Development Service and Partnership at WuXi AppTec. Prior to WuXi, he was EVP and CMO at Hutchison MediPharma in China. He previously held Medical Director and Head of Medical Affairs positions at several global pharmaceutical companies in the US, including Roche, Abraxis BioScience (Celgene/BMS), Biogen, and Genentech. With extensive experience in building and leading R&D organizations and international collaborations, Dr. Mu has a proven track record of successful development and approval of new drugs in China and around the globe. He participated in and led the development of more than 20 innovative drug candidates in multiple therapeutic areas, including three drugs approved in the US and global market, four in China, and an NDA currently under priority review in China.

Dr. Mu conducted translational and clinical research at the University of California, San Francisco and at the University of Washington Medical School before joining industry in 1999. He received his PhD in Genetic Epidemiology from the University of California at Berkeley and completed his post-doctorate training at University of California at San Francisco School of Medicine and University of Washington Medical School. Dr. Mu received his MD degree from West China University of Medical Sciences.

Our Investors

Agent Capital Logo
long-arrow-right-regularfacebook-brandsfacebook-f-brandsinstagram-brandslinkedin-brandslinkedin-in-brandssubmit-arrowtwitter-brandstwitter-square-brandsyoutube-brands